Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib with or without erlotinib in NSCLC
NCT00596648Phase 2Completed
- Sponsor
- Exelixis, Inc.
- Start
- Feb 2008
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in non-small cell lung cancer (NSCLC), sponsored by Exelixis, Inc.. Started Feb 2008; status: completed.
02
Drugs
cabozantinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00596648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00596648.